| Q93018032 | A model for RAS mutation patterns in cancers: finding the sweet spot |
| Q36082699 | ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold. |
| Q41525845 | Analysis of K-Ras Interactions by Biotin Ligase Tagging. |
| Q58753858 | Assessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling |
| Q90596163 | Avidity-driven polarity establishment via multivalent lipid-GTPase module interactions |
| Q38641451 | CRISPR-Cas9 Mediated Labelling Allows for Single Molecule Imaging and Resolution |
| Q37686308 | Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface |
| Q37308173 | Computational Equilibrium Thermodynamic and Kinetic Analysis of K-Ras Dimerization through an Effector Binding Surface Suggests Limited Functional Role. |
| Q37571072 | Computational and biochemical characterization of two partially overlapping interfaces and multiple weak-affinity K-Ras dimers |
| Q41045240 | Covalent Ras Dimerization on Membrane Surfaces through Photosensitized Oxidation. |
| Q91877720 | DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters |
| Q46264996 | Deciphering lipid codes: K-Ras as a paradigm |
| Q49721819 | Direct inhibition of RAS: Quest for the Holy Grail? |
| Q38911598 | Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design |
| Q93055781 | Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth |
| Q90211585 | Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling |
| Q38789349 | Distinct dynamics and interaction patterns in H- and K-Ras oncogenic P-loop mutants |
| Q38891257 | Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view |
| Q38702658 | Early and Late Induction of KRAS and HRAS Proto-Oncogenes by Reactive Oxygen Species in Primary Astrocytes. |
| Q47443285 | Efforts to Develop KRAS Inhibitors |
| Q36261640 | Elevated JMJD1A is a novel predictor for prognosis and a potential therapeutic target for gastric cancer |
| Q64939214 | Functional link between plasma membrane spatiotemporal dynamics, cancer biology, and dietary membrane-altering agents. |
| Q36323471 | GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site |
| Q90747731 | Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses |
| Q90647892 | Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer |
| Q40968374 | Independent and core pathways in oncogenic KRAS signaling |
| Q37540897 | Inhibition of RAS function through targeting an allosteric regulatory site. |
| Q99638636 | Inhibition of RAS: proven and potential vulnerabilities |
| Q37399041 | Insights from the Cold Transcriptome and Metabolome of Dendrobium officinale: Global Reprogramming of Metabolic and Gene Regulation Networks during Cold Acclimation |
| Q39361391 | Intrinsic protein disorder in oncogenic KRAS signaling |
| Q92100763 | Investigation of GTP-dependent dimerization of G12X K-Ras variants using ultraviolet photodissociation mass spectrometry |
| Q91814627 | K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function |
| Q47213711 | K-Ras4B Remains Monomeric on Membranes over a Wide Range of Surface Densities and Lipid Compositions. |
| Q38731776 | K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target? |
| Q55263196 | KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex. |
| Q92733424 | KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe |
| Q39195762 | KSR as a therapeutic target for Ras-dependent cancers. |
| Q49243022 | Lipid-Sorting Specificity Encoded in K-Ras Membrane Anchor Regulates Signal Output |
| Q36642191 | Mapping the functional versatility and fragility of Ras GTPase signaling circuits through in vitro network reconstitution |
| Q92769973 | Membrane interactions of the globular domain and the hypervariable region of KRAS4b define its unique diffusion behavior |
| Q38974930 | Membrane orientation dynamics of lipid-modified small GTPases |
| Q47568436 | Membrane-associated Ras dimers are isoform-specific: K-Ras dimers differ from H-Ras dimers |
| Q92631849 | Mitogen-Activated Protein Kinase Inhibitors and T-Cell-Dependent Immunotherapy in Cancer |
| Q78271812 | Modelling of Protein Kinase Signaling Pathways in Melanoma and Other Cancers |
| Q47144061 | Molecular Dynamics Simulations and Dynamic Network Analysis Reveal the Allosteric Unbinding of Monobody to H-Ras Triggered by R135K Mutation |
| Q39400435 | NF-κB as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer |
| Q37279704 | Nutrient-Gene Interaction in Colon Cancer, from the Membrane to Cellular Physiology. |
| Q36678717 | Oncogenic K-Ras Binds to an Anionic Membrane in Two Distinct Orientations: A Molecular Dynamics Analysis |
| Q47256433 | Oncogenic Ras Isoforms Signaling Specificity at the Membrane |
| Q50850523 | One-Pot N2C/C2C/N2N Ligation To Trap Weak Protein-Protein Interactions. |
| Q91656314 | Orai1 Promotes Osteosarcoma Metastasis by Activating the Ras-Rac1-WAVE2 Signaling Pathway |
| Q38765858 | PDEδ Binding to Ras Isoforms Provides a Route to Proper Membrane Localization. |
| Q58577211 | Pharmacological targeting of RAS: Recent success with direct inhibitors |
| Q88396870 | Phosphatidylserine and GTPase activation control Cdc42 nanoclustering to counter dissipative diffusion |
| Q54940071 | Phosphorylated EGFR Dimers Are Not Sufficient to Activate Ras. |
| Q91530322 | Phosphorylated Rho-GDP directly activates mTORC2 kinase towards AKT through dimerization with Ras-GTP to regulate cell migration |
| Q42512195 | Phosphorylation of the C-Raf N-region promotes Raf dimerization |
| Q36765168 | Plasma membrane regulates Ras signaling networks |
| Q90558686 | Presence or Absence of Ras Dimerization Shows Distinct Kinetic Signature in Ras-Raf Interaction |
| Q38614956 | Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation |
| Q90595812 | Quantitative biophysical analysis defines key components modulating recruitment of the GTPase KRAS to the plasma membrane |
| Q39407402 | RAS Proteins and Their Regulators in Human Disease |
| Q50469128 | RAS signaling: Divide and conquer. |
| Q96302844 | RAS-targeted therapies: is the undruggable drugged? |
| Q33646519 | Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target |
| Q49921459 | Ras and the Plasma Membrane: A Complicated Relationship |
| Q93187775 | Ras functional proximity proteomics establishes mTORC2 as new direct ras effector |
| Q35961154 | Seeing is believing: Ras dimers observed in live cells |
| Q47323529 | Single-Molecule Study Reveals How Receptor and Ras Synergistically Activate PI3Kα and PIP3 Signaling. |
| Q39426816 | Single-molecule fluorescence microscopy review: shedding new light on old problems. |
| Q48138939 | Spatiotemporal Analysis of K-Ras Plasma Membrane Interactions Reveals Multiple High Order Homo-oligomeric Complexes. |
| Q36038664 | Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation. |
| Q39191453 | Structural Basis of Dimeric Rasip1 RA Domain Recognition of the Ras Subfamily of GTP-Binding Proteins |
| Q90681757 | Targeting the α4-α5 dimerization interface of K-RAS inhibits tumor formation in vivo |
| Q48151533 | Targeting the α4-α5 interface of RAS results in multiple levels of inhibition. |
| Q58056531 | The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants |
| Q36669604 | The disordered hypervariable region and the folded catalytic domain of oncogenic K-Ras4B partner in phospholipid binding |
| Q91641964 | The quaternary assembly of KRas4B with Raf-1 at the membrane |
| Q38740000 | The renewed battle against RAS-mutant cancers |
| Q57060145 | Therapeutic strategies to target RAS-mutant cancers |
| Q89087147 | Translational Dynamics of Lipidated Ras Proteins in the Presence of Crowding Agents and Compatible Osmolytes |
| Q90752351 | Two Distinct Structures of Membrane-associated Homodimers of GTP- and GDP-bound KRAS4B Revealed by Paramagnetic Relaxation Enhancement |